title: Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies.
abstract: Comprehensive evaluation of the cost-effectiveness of HPV vaccination in China has not previously been performed. The objective of this study was to evaluate vaccination as an alternative or addition to primary HPV screening with careHPV (Qiagen, Gaithersburg, USA), and to assess the threshold total cost per vaccinated girl (CVG) at which strategies involving vaccination would become viable compared to screening-only strategies in rural China. We used data from field studies in Shanxi Province to support modelling of HPV vaccination and screening, including local information on sexual behaviour, HPV prevalence, test accuracy, treatment protocols and costs. We evaluated several strategies involving screening once or twice per lifetime or at regular 5-yearly intervals, with or without vaccination of young females at age 15 years, assuming 70% coverage for both screening and vaccination. We also predicted cross-sectional cancer incidence each year to the year 2050 for a range of strategies. We found that strategies involving vaccination would be cost-effective at CVGs of US$50-54 or less, but at CVGs >$54, screening-only strategies would be more cost-effective. If vaccination of young cohorts is combined with two rounds of careHPV screening for women aged 30-59 years in 2012 and 2027, a predicted indicative 33% reduction in cervical cancer incidence by 2030 would be sustained until 2050, with incidence rates decreasing thereafter. In conclusion, taking into account estimated vaccine delivery costs (for 3 doses), a per-dose HPV vaccine cost of approximately <$9-14 would be required for strategies involving vaccination to be cost-effective. Overall, combined screening and vaccination approaches are required to maximise outcomes in rural China.
authors.affiliation: Cancer Epidemiology Research Unit, Cancer Council NSW, Woolloomooloo, New South Wales, Australia. karenc@nswcc.org.au
authors.forename: Karen
authors.initials: K
authors.lastname: Canfell
authors.forename: Ju-Fang
authors.initials: JF
authors.lastname: Shi
authors.forename: Jie-Bin
authors.initials: JB
authors.lastname: Lew
authors.forename: Robert
authors.initials: R
authors.lastname: Walker
authors.forename: Fang-Hui
authors.initials: FH
authors.lastname: Zhao
authors.forename: Leonardo
authors.initials: L
authors.lastname: Simonella
authors.forename: Jun-Feng
authors.initials: JF
authors.lastname: Chen
authors.forename: Rosa
authors.initials: R
authors.lastname: Legood
authors.forename: Megan A
authors.initials: MA
authors.lastname: Smith
authors.forename: Carolyn
authors.initials: C
authors.lastname: Nickson
authors.forename: You-Lin
authors.initials: YL
authors.lastname: Qiao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002681:China / Q000453:epidemiology; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D015233:Models, Statistical; D027383:Papillomaviridae / Q000302:isolation & purification*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D012424:Rural Population; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000517:prevention & control*; D014773:Virology / Q000379:methods*; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines